id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-299222-vmofcrim	Rivas‐Pollmar, María Isabel	Thromboprophylaxis in a patient with COVID‐19 and severe hemophilia A on emicizumab prophylaxis	2020-06-11		.txt	text/plain	1571	78	37	All rights reserved Due to uncertainty about the risk of an increased prothrombotic state in CAC in association with emicizumab prophylaxis, thromboprophylaxis with low molecular weight heparin (LMWH), enoxaparin 40 mg once daily, was started. Bearing in mind the low risk of thrombosis with emicizumab in SHA without inhibitors, but because some of the mechanisms associated with the risk of thrombosis described above could be risk factors for the development of CAC, and in the absence of literature or guidelines for the management of such patients, our consensus clinical decision was to administer prophylactic doses of LMWH and to monitor laboratory parameters to follow up the disease and cytokine release storm. But we proposed the use of prophylactic dose of LMWH in SHA on emicizumab treatment at diagnosis, based on the low rate of bleeding complications associated with its	./cache/cord-299222-vmofcrim.txt	./txt/cord-299222-vmofcrim.txt